Main Article Content


Monitoring level of methotrexate is not only aimed at monitoring effectiveness, but also safety aspects of the administration of high-dose methotrexate because the use of high-dose methotrexate is one of the problems associated with toxicity in various organs.  In the use of high-dose methotrexate, measurement of methotrexate is important to identify patients with a high risk of toxicity, particularly nephrotoxicity as well as for dosing guidelines for leucovorin therapy. The aim of this study was to analyze the safety of high-dose methotrexate on kidney function during chemotherapy consolidation phase in children with acute lymphoblastic leukemia. This was a longitudinal, observational prospective study conducted to determine the safety profile of high-dose methotrexate on kidney function during chemotherapy consolidation phase in children with acute lymphoblastic leukemia. Patients who met the inclusion criteria were given high-dose methotrexate according to the 2013 Indonesian ALL Chemotherapy Protocol. Measurement of methotrexate level and kidney function was done 3 times on each cycle of chemotherapy consolidation phase. Measurements were made on the 0, 24 and 48 hours after the first drop of high-dose methotrexate. This study had been reviewed by Ethics Committee of Dr. Soetomo Hospital Surabaya. There were 12 patients who met inclusion criteria and 6 patients among them had finished their chemotherapy consolidation phase completely. There was no significant change in kidney function after the administration of high-dose methotrexate compared to baseline (p>0.05) and there was no significant correlation between serum level of methotrexate versus creatinine clearance. In conclusion, methotrexate was safe to use in children with acute lymphoblastic leukemia.


High-dose Methotrexate Kidney Function Acute Lymphoblastic Leukemia Consolidation Phase

Article Details

How to Cite
Utomo, F. N., Yulistiani, Y., Zairina, N., & Permono, B. (2017). METHOTREXATE USE IS SAFE IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA. Folia Medica Indonesiana, 53(2), 144–151.


  1. Alldredge BK, Corelli RL, Ernst ME, et al (2013). Koda-kimble & young's applied therapeutics: the clinical use of drugs, 10th Ed. Philadelphia, Lippincott Williams & Wilkins
  2. Bleyer WA and Dedrick RL (1978). Clinical pharma-cology of intrathecal methotrexate i pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treatment Reports Vol 61, 703-8
  3. Borsi JD and Moe PJ (1987). A comparative study on pharmacokinetics of methotrexate in a dose range of 0,5 g to 33,6 g/m2 in children with acute lympho-blastic leukemia. Cancer Vol 60, 5-13
  4. Hallworth MJ and Capps NE, 1993. Therapeutic drug monitoring and clinical biochemistry. London, ACB Venture Publications, p 70-73
  5. Hempel L, Misselwitz J, Fleck C, et al (2003). Influence of high dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Medical Pediatric Oncology Vol 40, 348-354
  6. Jacobs SA, Stoller RG, Chabner BA, et al (1976). 7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. The Journal of Clinical Investigation Vol 57, 534-538
  7. Kliegman RM, Stanton BF, St. Geme JW, et al (2016). Nelson Textbook of Pediatrics, 20th Ed. Philadelphia, Elsevier, p 2437-244
  8. Lennard L (1999). Therapeutic drug monitoring of antimetabolic cytotoxic drug. British Journal of Clinical Pharmacology Vol 47, 131-143
  9. Odoul F, Le Guellec C, Lamagnere JP, et al (1999). Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukemia using a population pharmacokinetic appro-ach. Fundamental Clinical Pharmacology Vol 13, 595-604
  10. Rau T, Erney B, Gores R, et al (2006). High-dose methotrexate in pediatric acute lymphoblastic leuke-mia: Impact of ABCC2 polymorphisms on plasma concentration. Clinical Pharmacology Therapy Vol 80, 468-76
  11. Sahnl V, Choudhury D, Ahmed Z (2009). Chemo-therapy-associated renal dysfunction. Nature Reviews Nephrology Vol 6, 450-462
  12. Xu WQ, Zhang LY, Chen XY, et al (2014). Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Che-motherapy Pharmacology Vol 73, 79-86

Most read articles by the same author(s)

1 2 > >>